AEACaP and Lung Cancer Europe (LuCE) host “ROS-1 Lung Cancer Patients” webinar on 26-Mar-2021


The Spanish Association of Lung Cancer Patients (AEACaP) and Lung Cancer Europe (LuCE) will be hosting the webinar “ROS-1 Lung Cancer Patients” on Friday, March 26th, 2021 at 18.00 Central European Time (10 am Pacific Time). The event will provide information about the ROS1 biomarker and treatment in lung cancer, as well as research and … Continue reading AEACaP and Lung Cancer Europe (LuCE) host “ROS-1 Lung Cancer Patients” webinar on 26-Mar-2021

Last Chance to register for @IASLC #TTLC21


LAST CHANCE to register for the IASLC 2020 Targeted Therapies in Lung Cancer Meeting (to be held THIS WEEK February 17-20). The program is a series of 5-minute presentations on lab research and clinical trials for targeted therapies. The session on ALK & ROS1 inhibitors happens on Thursday February 18 at 14:40 Eastern Time.   This … Continue reading Last Chance to register for @IASLC #TTLC21

Pulmonary hypertension in ROS1+ patients on TKIs


Two independent studies found ROS1+ lung cancer patients are more likely to develop blood clots than patients who have other lung cancers. Pulmonary embolisms are not uncommon in the ROS1ders, and these types of blood clots can eventually result in pulmonary hypertension (because it increases pressure on the heart). The appearance of a new blood … Continue reading Pulmonary hypertension in ROS1+ patients on TKIs

Calling all ROS1ders! Please help Australians access Entrectinib


For the first time, Australian ROS1+ lung cancer patients may have affordable access to Entrectnib. Currently, ROS1 patients cannot get access to Entrectnib outside of a clinical trial. We need the help of ROS1ders to make it happen. From 1 February 2020, Australian who have ROS1+ lung cancer may be able to purchase the medication … Continue reading Calling all ROS1ders! Please help Australians access Entrectinib

ROS1DERS: You can help Canadian ROS1+ NSCLC patients gain access to entrectinib!


Lung Cancer Canada (LCC) is seeking ROS1 positive non-small cell lung cancer (NSCLC) patients and caregivers who have past or present treatment experience with ENTRECTINIB to share their experiences. This information will be used to provide patient/caregiver input that will help in determining accessibility of this drug for lung cancer patients in Canada. LCC and … Continue reading ROS1DERS: You can help Canadian ROS1+ NSCLC patients gain access to entrectinib!

ROS1derings Winter 2020 (The ROS1ders newsletter)


Welcome to the Winter 2020 issue of ROS1derings, the newsletter of The ROS1ders! This issue contains info about on our patient-driven research, a fundraising update, a summary of current targeted therapies for ROS1+ cancers, and tips on parenting after a ROS1+ cancer diagnosis. Thanks to editors Joyce Hoelting and Jeff Wynne, and contributors Lisa Goldman, … Continue reading ROS1derings Winter 2020 (The ROS1ders newsletter)